Journal article
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
Journal of Clinical Neuroscience, Vol.21(11), pp.1847-1856
2014
Abstract
In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of β-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes.
Details
- Title
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
- Authors/Creators
- S.A. Broadley (Author/Creator) - Griffith UniversityM.H. Barnett (Author/Creator) - The University of SydneyM. Boggild (Author/Creator) - Townsville HospitalB.J. Brew (Author/Creator) - St Vincent's HealthH. Butzkueven (Author/Creator) - Eastern HealthR. Heard (Author/Creator) - The University of SydneyS. Hodgkinson (Author/Creator) - UNSW SydneyA.G. Kermode (Author/Creator) - The University of Western AustraliaJ. Lechner-Scott (Author/Creator) - Hunter Medical Research InstituteR.A.L. Macdonell (Author/Creator) - Austin HealthM. Marriott (Author/Creator) - The Royal Melbourne HospitalD.F. Mason (Author/Creator) - Christchurch HospitalJ. Parratt (Author/Creator) - The University of SydneyS.W. Reddel (Author/Creator) - The University of SydneyC.P. Shaw (Author/Creator) - Deakin UniversityM. Slee (Author/Creator) - Flinders Medical CentreJ. Spies (Author/Creator) - The University of SydneyB.V. Taylor (Author/Creator) - Menzies Research InstituteW.M. Carroll (Author/Creator) - The University of Western AustraliaT.J. Kilpatrick (Author/Creator) - Menzies Research InstituteJ. King (Author/Creator) - Florey Institute of Neuroscience and Mental HealthP.A. McCombe (Author/Creator) - The University of QueenslandJ.D. Pollard (Author/Creator) - The University of SydneyE. Willoughby (Author/Creator) - Auckland City Hospital
- Publication Details
- Journal of Clinical Neuroscience, Vol.21(11), pp.1847-1856
- Publisher
- Churchill Livingstone
- Identifiers
- 991005542889607891
- Copyright
- Crown Copyright © 2014
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
65 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.203 Neuromuscular Disorders
- 1.203.147 Multiple Sclerosis
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- ESI research areas
- Neuroscience & Behavior